No biomarker	Liposarcoma	No biomarker	Liposarcoma	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
CTNNB1 mutation	Endometrial Cancer	CTNNB1 mutation	Endometrial Cancer	PRI724 + SM04690 Sensitive: B - Late Trials PRI724 + SM04690 Sensitive : B	PRI724 + SM04690 Sensitive: B - Late Trials PRI724 + SM04690 Sensitive : B
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	eribulin mesylate Sensitive: B - Late Trials eribulin mesylate Sensitive : B	eribulin mesylate Sensitive: B - Late Trials eribulin mesylate Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	eribulin mesylate Sensitive: C2 – Inclusion Criteria eribulin mesylate Sensitive : C2	eribulin mesylate Sensitive: C2 – Inclusion Criteria eribulin mesylate Sensitive : C2

β-catenin inhibitor

β-catenin inhibitor

Associations(54)

Associations
(54)